

By: John A. Bauer  
Nelson Mullins Riley & Scarborough LLP  
280 Park Avenue, 15<sup>th</sup> Floor West  
New York, NY 10017  
(646) 428-2615 (telephone)  
(646) 428-2610 (facsimile)

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

GENOME & COMPANY,  
Petitioner

v.

THE UNIVERSITY OF CHICAGO,  
Patent Owner

---

Case No. PGR2019-00002  
U.S. Patent 9,855,302 B2

---

**PETITIONER'S OPPOSITION TO PATENT OWNER'S MOTION TO  
EXCLUDE EVIDENCE**

**TABLE OF CONTENTS**

	<b><u>Page</u></b>
TABLE OF AUTHORITIES .....	ii
TABLE OF EXHIBITS .....	iv
I. INTRODUCTION .....	1
II. ARGUMENT.....	2
A. Exhibit 1002 (First Declaration of Dr. Braun).....	2
B. Exhibit 1043 (Second Declaration of Dr. Braun) .....	4
C. Exhibit 1017 (O’Mahony).....	5
D. Exhibit 2005 (Sivan) .....	7
E. Exhibit 1044 (Sanchez).....	8
F. Exhibit 1028 (Thungappa) .....	9
G. Exhibit 1041 (Fares) .....	10
H. Exhibit 1032 (Kaiser).....	10
I. Exhibit 1033 (Snyder).....	11
J. Exhibit 1057 (Weber) .....	12
K. Exhibit 1023 ( <i>Targeted Cancer Therapies</i> ).....	12
L. Exhibit 1059 (Schultz Declaration) .....	14
III. CONCLUSION .....	14

**TABLE OF AUTHORITIES**

**Page(s)**

**Cases**

*Ariosa Diagnostics v. Verinata Health, Inc.*, 805 F.3d 1359 (Fed. Cir. 2015) ..... 13

*Arista Records LLC v. Usenet.com, Inc.*,  
608 F. Supp. 2d 409 (S.D.N.Y. 2009) ..... 2-4

*Celltrion, Inc. v. Genentech, Inc.*, IPR2017-01374,  
Paper 85 (PTAB Nov. 29, 2018) ..... 13

*Ericsson Inc. v. Intellectual Ventures I, LLC*, IPR2014-01149,  
Paper 68 (PTAB Dec. 9, 2015) ..... 13

*Fox Factory, Inc. v. SRAM, LLC*, IPR2016-01876,  
Paper 59 (PTAB Apr. 2, 2018)..... 12

*Incyte Corp. v. Concert Pharms., Inc.*, IPR2017-01256,  
Paper 119 (PTAB Apr. 8, 2019)..... 10

*Intex Rec. Corp. v. Team Worldwide Corp.*, IPR2018-00859,  
Paper 128 (PTAB Oct. 21, 2019) ..... 5

*Nichia Corp. v. Emcore Corp.*, IPR2012-00005,  
Paper 68 (PTAB Feb. 11, 2014)..... 2, 5, 10, 13, 14

*Phillips v. AWH Corp.*, 415 F.3d 1303 (Fed. Cir. 2005) (*en banc*) ..... 8

*Randall Mfg. v. Rea*, 733 F.3d 1355 (Fed. Cir. 2013)..... 8

*S.E.C. v. Guenthner*, 395 F. Supp. 2d 835 (D. Neb. 2005) ..... 5, 10, 13, 14

*Wojciak v. Nishiyama*, 61 USPQ2d 1576 (B.P.A.I. 2001) ..... 6

*Yeda Research v. Mylan Pharm. Inc.*, 906 F.3d 1031 (Fed. Cir. 2018).....*passim*

**Rules**

37 C.F.R. § 42.65(a) ..... 5

**Other Authorities**

77 Fed. Reg. 6879 (February 9, 2012).....6

**TABLE OF EXHIBITS**

**Previously Filed Exhibits**

<b>Exhibit</b>	<b>Description</b>
1001	U.S. Patent No. 9,855,302
1002	First Declaration of Jonathan Braun, M.D., Ph.D.
1003	U.S. Publication No. 2009/027401 to Korman <i>et al.</i>
1004	Jagveer Singh <i>et al.</i> , <i>Bifidobacterium longum</i> , a lactic acid-producing intestinal bacterium inhibits colon cancer and modulated the intermediate biomarkers of colon carcinogenesis, <i>Carcinogenesis</i> (1997)
1005	Ping Dong <i>et al.</i> , <i>The role of intestinal Bifidobacteria on immune system development in young rats</i> , <i>Early Human Development</i> (2010)
1006	Suzanne L. Topalian <i>et al.</i> , <i>Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab</i> , <i>Journal of Clinical Oncology</i> (Apr. 1, 2014)
1007	Yoshinori Kohwi <i>et al.</i> , <i>Antitumor effect of Bifidobacterium Infantis in Mice</i> , <i>Gann</i> (Oct. 1978)
1008	Dheeraj Mohania <i>et al.</i> , <i>Modulation of expression of Programmed Death-1 by administration of probiotic Dahi in DMH-induced colorectal carcinogenesis in rats</i> , <i>Acta Biomed</i> (2013)
1009	U.S. Publication No. 2010/0028449 to Prakash <i>et al.</i>
1010	D. van der waaij <i>et al.</i> , <i>The Influence of antibiotics on gut colonizastion</i> , <i>Journal of Antimicrobial Chemotherapy</i> (1986)
1011	Do Kyung Lee <i>et al.</i> , <i>Anti-proliferative effects of Bifidobacterium adolescentis SPM0212 extract on human colon cancer cell lines</i> , <i>BMC Cancer</i> , (Oct. 2008)
1012	U.S. Provisional Patent Application No. 62/169,112
1013	U.S. Provisional Patent Application No. 62/248,741
1014	File History of U.S. Patent No. 9,855,302
1015	File History of U.S. Patent Application No. 15/718,735
1016	Elad Sharon <i>et al.</i> , <i>Immune checkpoints in cancer clinical trials</i> , <i>Chinese Journal of Cancer</i> (2014)
1017	U.S. Publication No. 2012/0276143 to O'Mahony <i>et al.</i>

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.